Johnson & Johnson’s Janssen unit has announced phase 3 results showing that its ponesimod tablet outperformed Sanofi’s Aubagio pill in adults with relapsing multiple sclerosis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,